During the last session, ProKidney Corp (NASDAQ:PROK)’s traded shares were 2.25 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $0.80, reflecting an intraday gain of 12.08% or $0.09. The 52-week high for the PROK share is $4.44, that puts it down -455.0 from that peak though still a striking 42.5% gain since the share price plummeted to a 52-week low of $0.46. The company’s market capitalization is $232.95M, and the average intraday trading volume over the past 10 days was 1.75 million shares, and the average trade volume was 639.88K shares over the past three months.
ProKidney Corp (PROK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.20. PROK has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
ProKidney Corp (NASDAQ:PROK) trade information
ProKidney Corp (PROK) registered a 12.08% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.08% in intraday trading to $0.80, hitting a weekly high. The stock’s 5-day price performance is 36.64%, and it has moved by -17.91% in 30 days. Based on these gigs, the overall price performance for the year is -61.92%. The short interest in ProKidney Corp (NASDAQ:PROK) is 11.93 million shares and it means that shorts have 21.42 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 84.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $6 respectively. As a result, PROK is trading at a discount of -650.0% off the target high and -275.0% off the low.
ProKidney Corp (PROK) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
While earnings are projected to return 3.70% in 2025, the next five years will return -3.33% per annum.
PROK Dividends
ProKidney Corp is due to release its next quarterly earnings on 2025-Mar-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ProKidney Corp (NASDAQ:PROK)’s Major holders
ProKidney Corp insiders own 28.29% of total outstanding shares while institutional holders control 44.37%, with the float percentage being 61.88%. SUVRETTA CAPITAL MANAGEMENT, LLC is the largest shareholder of the company, while 108.0 institutions own stock in it. As of 2024-06-30, the company held over 9.34 million shares (or 12.306% of all shares), a total value of $22.98 million in shares.
The next largest institutional holding, with 3.66 million shares, is of BLACKROCK INC.’s that is approximately 4.8167% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $8.99 million.
Also, the Mutual Funds coming in first place with the largest holdings of ProKidney Corp (PROK) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 2.97 shares. This amounts to just over 2.29 percent of the company’s overall shares, with a $2.36 million market value. The same data shows that the other fund manager holds slightly less at 2.92, or about 2.26% of the stock, which is worth about $2.33 million.
